Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Aug;40(4):100931.
doi: 10.1016/j.accpm.2021.100931. Epub 2021 Jul 10.

French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study

Claire Roger  1 , Olivier Collange  2 , Myriam Mezzarobba  3 , Osama Abou-Arab  4 , Lauranne Teule  5 , Marc Garnier  6 , Clément Hoffmann  7 , Laurent Muller  8 , Jean-Yves Lefrant  8 , Pierre Grégoire Guinot  9 , Emmanuel Novy  10 , Paul Abraham  11 , Thomas Clavier  12 , Jérémy Bourenne  13 , Guillaume Besch  14 , Laurent Favier  15 , Michel Fiani  16 , Alexandre Ouattara  17 , Olivier Joannes-Boyau  17 , Marc-Olivier Fischer  18 , Marc Leone  19 , Younes Ait Tamlihat  20 , Julien Pottecher  21 , Pierre-Yves Cordier  22 , Philippe Aussant  23 , Mouhamed Djahoum Moussa  24 , Etienne Hautin  25 , Marine Bouex  26 , Jean-Michel Julia  27 , Julien Cady  28 , Marc Danguy Des Déserts  29 , Nicolas Mayeur  30 , Thibault Mura  3 , Bernard Allaouchiche  31 ; AZUREA group
Affiliations
Observational Study

French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study

Claire Roger et al. Anaesth Crit Care Pain Med. 2021 Aug.

Abstract

Aim: Describing acute respiratory distress syndrome patterns, therapeutics management, and outcomes of ICU COVID-19 patients and indentifying risk factors of 28-day mortality.

Methods: Prospective multicentre, cohort study conducted in 29 French ICUs. Baseline characteristics, comorbidities, adjunctive therapies, ventilatory support at ICU admission and survival data were collected.

Results: From March to July 2020, 966 patients were enrolled with a median age of 66 (interquartile range 58-73) years and a median SAPS II of 37 (29-48). During the first 24 h of ICU admission, COVID-19 patients received one of the following respiratory supports: mechanical ventilation for 559 (58%), standard oxygen therapy for 228 (24%) and high-flow nasal cannula (HFNC) for 179 (19%) patients. Overall, 721 (75%) patients were mechanically ventilated during their ICU stay. Prone positioning and neuromuscular blocking agents were used in 494 (51%) and 460 (48%) patients, respectively. Bacterial co-infections and ventilator-associated pneumonia were diagnosed in 79 (3%) and 411 (43%) patients, respectively. The overall 28-day mortality was 18%. Age, pre-existing comorbidities, severity of respiratory failure and the absence of antiviral therapy on admission were identified as independent predictors of 28-day outcome.

Conclusion: Severity of hypoxaemia on admission, older age (> 70 years), cardiovascular and renal comorbidities were associated with worse outcome in COVID-19 patients. Antiviral treatment on admission was identified as a protective factor for 28-day mortality. Ascertaining the outcomes of critically ill COVID-19 patients is crucial to optimise hospital and ICU resources and provide the appropriate intensity level of care.

Keywords: COVID-19; Management; Outcome; Viral pneumonia.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow Diagram.
Fig. 2
Fig. 2
Kaplan-Meyer survival estimates during the 28 days following intensive care unit admission according to PaO2/FIO2 ratio in mmHg at admission. PaO2: partial oxygen arterial blood pressure. FIO2: fraction of inspired oxygen
See this image and copyright information in PMC

References

    1. Aziz S., Arabi Y.M., Alhazzani W., Evans L., Citerio G., Fischkoff K. Managing ICU surge during the COVID-19 crisis: rapid guidelines. Intensive Care Med. 2020;46(7):1303–1325. - PMC - PubMed
    1. Gattinoni L., Chiumello D., Caironi P., Busana M., Romitti F., Brazzi L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46(6):1099–1102. - PMC - PubMed
    1. Guerin C., Albert R.K., Beitler J., Gattinoni L., Jaber S., Marini J.J. Prone position in ARDS patients: why, when, how and for whom. Intensive Care Med. 2020;46:2385–2396. - PMC - PubMed
    1. Group R.C., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020;384:693–704. - PMC - PubMed
    1. Group R.C. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. - PMC - PubMed

Publication types